Analysis / Atenolol

PharmaceuticalsC₁₄H₂₂N₂O₃CAS 29122-68-7

Atenolol

Cities measured

87

Detected in

87 / 87

Highest

0.068 μg/L — Delhi

Overview

Atenolol is a beta-blocker widely prescribed for hypertension and cardiac conditions. It is excreted largely unchanged and is among the most detected cardiovascular drugs in European wastewater. Conventional treatment removes 20–60%.

Health Relevance

In aquatic organisms, beta-blockers can affect heart rate regulation in fish at μg/L concentrations. At drinking water trace concentrations, direct human effects are not documented.

Regulatory Limits

EU

Drinking Water Directive 2020/2184

No EU regulatory limit.

Controversy & Contested Science

Atenolol is part of a broader regulatory gap: the EU Drinking Water Directive (2020/2184) introduced pharmaceutical monitoring (Watch List) without binding limits. Critics argue the Watch List model perpetually defers action — utilities monitor, submit data, and continue discharging pharmaceutically contaminated effluent without consequence. Binding limits require costly treatment upgrades; the absence of limits defers these costs indefinitely. This regulatory design may reflect economic pressure from utilities and member states rather than a genuine assessment of health risk.